Research, Strokes and TAVR - Cardiovascular Update

There’s No Clear King of TAVR Valves

CardiacWire

FEBRUARY 26, 2025

Cardiologists have a wide selection of TAVR valves to choose from, and a new study pitting the top three second generation devices against each other suggests theres not much difference in the long run. So far, we havent known the long-term clinical outcomes of second-generation devices for TAVR beyond five years after implantation.

TAVR

TAVR Hospital Research Strokes

TAVR System Shows Durable Clinical Outcomes, Strong Valve Performance in Low-Risk Aortic Stenosis Patients

DAIC

MARCH 31, 2025

Data shows, versus surgery, the Evolut transcatheter aortic valve replacement (TAVR) system delivers a numerically lower rate of all-cause mortality or disabling stroke at five years, strong valve performance and durable clinical outcomes. Evolut TAVR vs. 9.3% Evolut TAVR vs. 9.3% Reardon, M.D., Grubb, M.D., 1 Herrmann H.

TAVR

TAVR Stenosis Aortic Outcomes

Brain-Protected TAVR Results in Fewer Real-World Disabling Strokes

Med Page Today

JUNE 5, 2024

(MedPage Today) -- NEW YORK CITY -- Researchers eked out evidence of a small clinical benefit with the Sentinel cerebral embolic protection (CEP) device in transcatheter aortic valve replacement (TAVR) -- and pointed to the patients more likely.

TAVR

TAVR Aortic valve Embolism Aortic

Webinars

Bridging Innovation & Patient Care: The Growing Role of AI

MORE WEBINARS

Almost 50% of Patients Under 60 Years Choose TAVR Over Surgical Aortic Valve Replacement with Worse Outcomes

DAIC

JANUARY 29, 2024

By 2021 almost half of patients younger than 60 years were receiving TAVR rather than SAVR. The research team followed these patients for a median time of 2.4 years after TAVR and 4.9 Secondary outcomes included rates of reoperation, infective endocarditis, stroke, and hospital admissions for heart failure.

Aortic valve

Aortic valve TAVR Aortic Outcomes

STS Announces Late-breaker Research to Be Presented at the 2024 Annual Meeting

DAIC

JANUARY 29, 2024

milla1cf Mon, 01/29/2024 - 11:00 January 29, 2024 — The Society of Thoracic Surgeons has released late-breaking research scheduled for presentation at the 2024 Annual Meeting taking place January 27 - 29 in San Antonio. The findings underscore the escalating need for both aortic and non-aortic valve cardiac surgeries following TAVR.

Research

Research TAVR Aortic valve Atrial Fibrillation

Evolut Low Risk: TAVR Noninferior to SAVR at 5-Year Follow-Up

American College of Cardiology

MARCH 30, 2025

Patients with severe aortic stenosis who were treated with either TAVR or surgery had comparable rates of all-cause mortality or disabling stroke at five years, according to research presented during a Late-Breaking Clinical Trial session at ACC.25 25 in Chicago and simultaneously published in JACC.

TAVR

TAVR Stenosis Aortic Research

SAVR After TAVR Risk Calculator

Society of Thoracic Surgeons - Congenital

APRIL 12, 2024

Resource SAVR After TAVR Risk Calculator kchalko Fri, 04/12/2024 - 13:53 SAVR after previous TAVR is the fastest-growing cardiac surgery procedure in the U.S. The majority of patients require explant of their TAVR device and SAVR with significantly increased risk of operative mortality and stroke.

TAVR

TAVR Patient Care Outcomes Research

DAIC's Top 10 for June

DAIC

JULY 2, 2024

Multiple Randomized Trials Prove More Stroke Patients Can Benefit from Thrombectomy 4. HonorHealth Research Institute Study Uses New Programing for Pacemakers to Control High Blood Pressure Without Additional Drugs 6. Atlantic Health System’s Morristown Medical Center Tops 5,000 TAVR Procedures 8.

Blood Pressure

Blood Pressure TAVR Technology Aortic

New Late-breaking Data from Medtronic Evolut Low Risk Trial Demonstrate Strong Clinical and Cost-effectiveness Benefits of TAVR Platform

DAIC

MARCH 12, 2024

A cost-effectiveness analysis demonstrates the positive economic value of transcatheter aortic valve replacement (TAVR) using Evolut TAVR compared to surgical aortic valve replacement (SAVR) for low-risk patients. The findings showed a strong economic benefit of Evolut TAVR for low-risk patients from a U.S.

TAVR

TAVR Aortic valve Aortic Stenosis

Modified percutaneous coronary intervention-derived risk models (PARIS and CREDO-Kyoto integer scoring systems) applied to Japanese transcatheter aortic valve replacement patients

Open Heart

JANUARY 19, 2023

Objective Postprocedural ischaemic and bleeding risks after transcatheter aortic valve replacement (TAVR) remain a major concern. We aimed to assess the accuracy of percutaneous coronary intervention (PCI)-derived models and the performance of a recalibrated model that included variables more applicable to TAVR.

Aortic valve

Aortic valve TAVR Aortic Myocardial Infarction

Transcatheter aortic valve replacement in heart failure

European Journal of Heart Failure

JANUARY 31, 2024

TAVR in heart failure. The use of transcatheter aortic valve replacement (TAVR) has become the preferred therapy for most patients with AS and concomitant HF. The prognostic covariates and optimal timing of TAVR in patients with less than severe AS remain unclear.

Aortic valve

Aortic valve Heart Failure Aortic TAVR

Impact of prior coronary artery bypass grafting and coronary lesion complexity on outcomes of transcatheter aortic valve replacement for severe aortic stenosis

Coronary Artery Disease Journal

MAY 13, 2024

Objective To investigate the impact of prior coronary artery bypass grafting (CABG) and coronary lesion complexity on transcatheter aortic valve replacement (TAVR) outcomes for aortic stenosis. Conclusion Prior CABG may positively affect mid-term TAVR outcomes for aortic stenosis compared with no CAD when adjusted for other comorbidities.

Coronary Artery Bypass Graft

Coronary Artery Bypass Graft Aortic valve Aortic Stenosis

American College of Cardiology ACC.24 Late-breaking Science and Guidelines Session Summary

DAIC

FEBRUARY 29, 2024

Five highly-anticipated late-breaking clinical trial sessions, an ACC/AHA guidelines update session and a host of featured clinical research sessions have been announced by program planners for the American College of Cardiology’s 73 rd Annual Scientific Session & Expo to be held April 6-8 in Atlanta, GA. The Guidelines Sessions at ACC.24

Aortic valve

Aortic valve Myocardial Infarction Aortic Blood Pressure

The Weekend Effect Touches TAVR Too

CardiacWire

FEBRUARY 7, 2025

It seems even interventional cardiologists arent immune to the Weekend Effect as a recent study suggests patients admitted on weekends for TAVR procedures face significantly higher risks. The post The Weekend Effect Touches TAVR Too appeared first on Cardiac Wire.

TAVR

TAVR Cardiogenic Shock Hospital Cardiac Arrest

New Data for Medtronic CoreValve/Evolut TAVR Systems Reinforces Excellent Valve Performance

DAIC

JUNE 7, 2024

milla1cf Fri, 06/07/2024 - 14:50 June 7, 2024 — Medtronic today announced new data from the CoreValve Evolut Clinical Program , reinforcing the positive performance of the Evolut transcatheter aortic valve replacement (TAVR) System compared to surgical aortic valve replacement (SAVR) and other TAVR valves. Evolut vs. 10.6%

TAVR

TAVR Aortic valve Aortic Stenosis

Lifelong risk of stroke after TAVR: Findings from SwissTAVI Registry

Cardiology Update

FEBRUARY 6, 2024

Stroke stands as a major contributor to global morbidity and mortality, imposing a substantial burden on patients, societies, and healthcare systems worldwide. Within the realm of transcatheter aortic valve replacement (TAVR), stroke emerges as a recognized adverse event, manifesting at various stages during and after the procedure.

TAVR

TAVR Strokes Stroke Aortic valve

TAVR Found Non-Inferior to SAVR for Low-Risk Patients

DAIC

APRIL 11, 2024

TAVR and SAVR are procedures to replace a damaged aortic valve that is not functioning properly. TAVR and SAVR are procedures to replace a damaged aortic valve that is not functioning properly. The DEDICATE-DZHK6 trial compared TAVR vs. SAVR in 1,414 patients who underwent valve replacement procedures at 38 centers in Germany.

TAVR

TAVR Aortic valve Aortic COVID-19

Self-Expanding Valve Outperforms Balloon-Expandable Valve for TAVR in Patients with Small Valve Annulus

DAIC

APRIL 9, 2024

The SMART trial is the first randomized head-to-head comparison of the two most widely used TAVR devices—the supra-annular self-expanding Evolut PRO/PRO+/FX and the balloon-expandable SAPIEN 3/3 Ultra. The trial enrolled 716 patients who underwent TAVR at 83 international sites in North America, Europe and the Middle East.

TAVR

TAVR Aortic valve Aortic Anatomy

Transcatheter Valve Replacement Outcomes Similar to Surgery in Long-Term Analysis

DAIC

MAY 15, 2024

Getty Images milla1cf Wed, 05/15/2024 - 19:10 May 15, 2024 — A new study demonstrated parity between a minimally invasive procedure to replace the aortic valve in the heart— transcatheter aortic valve replacement (TAVR)—and surgical aortic valve replacement (SAVR). 1.11, p=0.70) with similar long-term mortality risks.

Aortic valve

Aortic valve TAVR Outcomes Aortic

Groundbreaking Data in Interventional Cardiology to be Featured at Society for Cardiovascular Angiology and Interventions SCAI 2024 Scientific Sessions

DAIC

MAY 1, 2024

The Society for Cardiovascular Angiography & Interventions (SCAI) kicks off its SCAI Scientific Sessions 2024 this week, May 2-4 in Long Beach, CA, bringing together more than 1,800 clinicians, scientists, researchers, and innovators in the field of interventional cardiology and endovascular medicine. Sinai Hospital (New York, NY).

Interventional Cardiology

Interventional Cardiology Aortic valve TAVR Peripheral Arterial Disease

Redo-TAVR with balloon-expandable valves: outcomes from a national registry

Cardiology Update

NOVEMBER 26, 2023

In light of the growing number of patients undergoing transcatheter aortic valve replacement (TAVR), there is an increasing demand for data regarding the management of failed TAVR procedures, including the possibility of a repeat TAVR intervention. vs. 19.0%, p=0.57), as well as stroke at 30 days (2.0% vs. 3.3%, p=0.18).

TAVR

TAVR Aortic valve Outcomes Aortic

Abstract TP316: Stroke Events in Cancer Versus Non-Cancer Patients With Aortic Stenosis During Transcatheter Aortic Valve Replacement

Stroke Journal

JANUARY 30, 2025

Stroke, Volume 56, Issue Suppl_1 , Page ATP316-ATP316, February 1, 2025. Background:Despite improvements in the safety of transcatheter aortic valve replacement (TAVR), ~4% of patients experience a procedure-related stroke. We assessed if there was a difference in stroke events between cancer and non-cancer patients.

Aortic valve

Aortic valve Cancer Aortic Stenosis

Transcarotid Versus Surgical Aortic Valve Replacement for the Treatment of Severe Aortic Stenosis

Circulation: Cardiovascular Interventions

MARCH 26, 2025

Transcarotid transcatheter aortic valve replacement (TC-TAVR) has emerged as an alternative access in suboptimal transfemoral candidates, but no data exist comparing TC-TAVR and SAVR. At 30 days, the SAVR group showed a higher rate of the primary composite outcome compared with the TC-TAVR group (12.6% andP=0.001, respectively).

Aortic valve

Aortic valve Aortic Stenosis TAVR

Rationale and Design of the CREATE Trial: A Multicenter, Randomized Comparison of Continuation or Cessation of Single Antithrombotic Therapy at 1 Year After Transcatheter Aortic Valve Replacement

Journal of the American Heart Association

MARCH 21, 2025

The primary efficacy end point is the incidence of bleeding events, defined by the VARC3 (Valve Academic Research Consortium3) criteria, at 1year postrandomization. The primary safety end point is a composite of cardiac death, myocardial infarction, and ischemic stroke at 1 year.

Aortic valve

Aortic valve Aortic Myocardial Infarction TAVR

Highlights of ACC 2024

Cardiology Update

APRIL 9, 2024

SMART 4 ( NCT04722250 ) studied patients with severe aortic stenosis and a small aortic annulus who underwent transcatheter aortic valve replacement (TAVR). A total of 716 patients underwent TAVR with either a self-expanding supraannular valve or a balloon-expandable valve. vs. 6.2%) and stroke (2.9% vs. 4.7%) compared to SAVR.

Angina

Angina Myocardial Infarction Aortic valve Coronary Artery Disease

Published Research

Society of Thoracic Surgeons - Research

APRIL 20, 2023

Published Research kschukar Thu, 04/20/2023 - 11:12 Recently published (2016 – present) manuscripts utilizing STS data: Adult Cardiac Surgery, General Thoracic Surgery, Congenital Heart Surgery, and Intermacs/Pedimacs.

Research

Research Coronary Artery Bypass Graft Aortic valve Congenital

Published Research

Society of Thoracic Surgeons - Research

APRIL 20, 2023

Published Research kschukar Thu, 04/20/2023 - 11:12 Recently published (2016 – present) manuscripts utilizing STS data: Adult Cardiac Surgery, General Thoracic Surgery, Congenital Heart Surgery, and Intermacs/Pedimacs.

Research

Research Coronary Artery Bypass Graft Aortic valve Congenital

TCT 2024’s Top TAVR Studies

CardiacWire

NOVEMBER 3, 2024

This year’s TCT conference saw a deluge of TAVR studies examining everything from the efficacy of valve designs to TAVR’s impact on aortic and tricuspid regurgitation. Patients who received early TAVR were 16% less likely to experience MACE and saw better heart function over a median of 3.8

TAVR

TAVR Embolism Interventional Cardiology Aortic

There’s No Clear King of TAVR Valves

TAVR System Shows Durable Clinical Outcomes, Strong Valve Performance in Low-Risk Aortic Stenosis Patients

Brain-Protected TAVR Results in Fewer Real-World Disabling Strokes

Webinars

Almost 50% of Patients Under 60 Years Choose TAVR Over Surgical Aortic Valve Replacement with Worse Outcomes

STS Announces Late-breaker Research to Be Presented at the 2024 Annual Meeting

Evolut Low Risk: TAVR Noninferior to SAVR at 5-Year Follow-Up

SAVR After TAVR Risk Calculator

DAIC's Top 10 for June

New Late-breaking Data from Medtronic Evolut Low Risk Trial Demonstrate Strong Clinical and Cost-effectiveness Benefits of TAVR Platform

Modified percutaneous coronary intervention-derived risk models (PARIS and CREDO-Kyoto integer scoring systems) applied to Japanese transcatheter aortic valve replacement patients

Transcatheter aortic valve replacement in heart failure

Impact of prior coronary artery bypass grafting and coronary lesion complexity on outcomes of transcatheter aortic valve replacement for severe aortic stenosis

American College of Cardiology ACC.24 Late-breaking Science and Guidelines Session Summary

The Weekend Effect Touches TAVR Too

New Data for Medtronic CoreValve/Evolut TAVR Systems Reinforces Excellent Valve Performance

Lifelong risk of stroke after TAVR: Findings from SwissTAVI Registry

TAVR Found Non-Inferior to SAVR for Low-Risk Patients

Self-Expanding Valve Outperforms Balloon-Expandable Valve for TAVR in Patients with Small Valve Annulus

Transcatheter Valve Replacement Outcomes Similar to Surgery in Long-Term Analysis

Groundbreaking Data in Interventional Cardiology to be Featured at Society for Cardiovascular Angiology and Interventions SCAI 2024 Scientific Sessions

Redo-TAVR with balloon-expandable valves: outcomes from a national registry

Abstract TP316: Stroke Events in Cancer Versus Non-Cancer Patients With Aortic Stenosis During Transcatheter Aortic Valve Replacement

Transcarotid Versus Surgical Aortic Valve Replacement for the Treatment of Severe Aortic Stenosis

Rationale and Design of the CREATE Trial: A Multicenter, Randomized Comparison of Continuation or Cessation of Single Antithrombotic Therapy at 1 Year After Transcatheter Aortic Valve Replacement

Highlights of ACC 2024

Published Research

Published Research

TCT 2024’s Top TAVR Studies

Stay Connected